Targeting NFATc4 attenuates non-alcoholic steatohepatitis in mice

Michelotti, 2013, NAFLD, NASH and liver cancer, Nat Rev Gastroenterol Hepatol, 10, 656, 10.1038/nrgastro.2013.183 Marra, 2008, Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis, Trends Mol Med, 14, 72, 10.1016/j.molmed.2007.12.003 Wree, 2013, From NAFLD to NASH to cirrhosis–new insights into disease mechanisms, Nat Rev Gastroenterol Hepatol, 10, 627, 10.1038/nrgastro.2013.149 Tilg, 2010, Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis, Hepatology, 52, 1836, 10.1002/hep.24001 Clark, 2003, Nonalcoholic fatty liver disease: an underrecognized cause of cryptogenic cirrhosis, JAMA, 289, 3000, 10.1001/jama.289.22.3000 Sanyal, 2001, Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities, Gastroenterology, 120, 1183, 10.1053/gast.2001.23256 Kojima, 2007, Mitochondrial abnormality and oxidative stress in nonalcoholic steatohepatitis, Alcohol Clin Exp Res, 31, S61, 10.1111/j.1530-0277.2006.00288.x Rao, 1997, Transcription factors of the NFAT family: regulation and function, Annu Rev Immunol, 15, 707, 10.1146/annurev.immunol.15.1.707 Lopez-Rodriguez, 1999, NFAT5, a constitutively nuclear NFAT protein that does not cooperate with Fos and Jun, Proc Natl Acad Sci U S A, 96, 7214, 10.1073/pnas.96.13.7214 Timmerman, 1996, Rapid shuttling of NF-AT in discrimination of Ca2+ signals and immunosuppression, Nature, 383, 837, 10.1038/383837a0 Crabtree, 1994, Signal transmission between the plasma membrane and nucleus of T lymphocytes, Annu Rev Biochem, 63, 1045, 10.1146/annurev.bi.63.070194.005145 Wu, 2007, NFAT signaling and the invention of vertebrates, Trends Cell Biol, 17, 251, 10.1016/j.tcb.2007.04.006 Schulz, 2004, Calcineurin signaling and NFAT activation in cardiovascular and skeletal muscle development, Dev Biol, 266, 1, 10.1016/j.ydbio.2003.10.008 Ranger, 1998, The transcription factor NF-ATc is essential for cardiac valve formation, Nature, 392, 186, 10.1038/32426 Liu, 2012, Interaction between NFkappaB and NFAT coordinates cardiac hypertrophy and pathological remodeling, Circ Res, 110, 1077, 10.1161/CIRCRESAHA.111.260729 Ho, 1998, A potential role for the nuclear factor of activated T cells family of transcriptional regulatory proteins in adipogenesis, Proc Natl Acad Sci U S A, 95, 15537, 10.1073/pnas.95.26.15537 Yang, 2006, Role of transcription factor NFAT in glucose and insulin homeostasis, Mol Cell Biol, 26, 7372, 10.1128/MCB.00580-06 Huang, 2017, PARP1-mediated PPARalpha poly(ADP-ribosyl)ation suppresses fatty acid oxidation in non-alcoholic fatty liver disease, J Hepatol, 66, 962, 10.1016/j.jhep.2016.11.020 Syn, 2010, Accumulation of natural killer T cells in progressive nonalcoholic fatty liver disease, Hepatology, 51, 1998, 10.1002/hep.23599 Ray, 2010, Isolation of mouse peritoneal cavity cells, J Vis Exp, 35, 1488 Yamaguchi, 2007, Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis, Hepatology, 45, 1366, 10.1002/hep.21655 Sahai, 2004, Obese and diabetic db/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis: role of short-form leptin receptors and osteopontin, Am J Physiol Gastrointest Liver Physiol, 287, G1035, 10.1152/ajpgi.00199.2004 Larter, 2008, Animal models of NASH: getting both pathology and metabolic context right, J Gastroenterol Hepatol, 23, 1635, 10.1111/j.1440-1746.2008.05543.x Clapper, 2013, Diet-induced mouse model of fatty liver disease and nonalcoholic steatohepatitis reflecting clinical disease progression and methods of assessment, Am J Physiol Gastrointest Liver Physiol, 305, G483, 10.1152/ajpgi.00079.2013 Molkentin, 1998, A calcineurin-dependent transcriptional pathway for cardiac hypertrophy, Cell, 93, 215, 10.1016/S0092-8674(00)81573-1 Day, 1998, Steatohepatitis: a tale of two “hits”?, Gastroenterology, 114, 842, 10.1016/S0016-5085(98)70599-2 Lebensztejn, 2016, Hepatokines and non-alcoholic fatty liver disease, Acta Biochim Pol, 63, 459, 10.18388/abp.2016_1252 Bohinc, 2012, Mechanisms of disease progression in NASH: new paradigms, Clin Liver Dis, 16, 549, 10.1016/j.cld.2012.05.002 Chabas, 2001, The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease, Science, 294, 1731, 10.1126/science.1062960 Rangaswami, 2006, Osteopontin: role in cell signaling and cancer progression, Trends Cell Biol, 16, 79, 10.1016/j.tcb.2005.12.005 Miyazaki, 2008, Corneal wound healing in an osteopontin-deficient mouse, Invest Ophthalmol Vis Sci, 49, 1367, 10.1167/iovs.07-1007 Patouraux, 2012, The osteopontin level in liver, adipose tissue and serum is correlated with fibrosis in patients with alcoholic liver disease, PLoS One, 7, e35612, 10.1371/journal.pone.0035612 Coombes, 2015, Osteopontin neutralisation abrogates the liver progenitor cell response and fibrogenesis in mice, Gut, 64, 1120, 10.1136/gutjnl-2013-306484 Bertola, 2009, Elevated expression of osteopontin may be related to adipose tissue macrophage accumulation and liver steatosis in morbid obesity, Diabetes, 58, 125, 10.2337/db08-0400 Many, 2016, OPN-a induces muscle inflammation by increasing recruitment and activation of pro-inflammatory macrophages, Exp Physiol, 101, 1285, 10.1113/EP085768 Nilsson-Berglund, 2010, Nuclear factor of activated T cells regulates osteopontin expression in arterial smooth muscle in response to diabetes-induced hyperglycemia, Arterioscler Thromb Vasc Biol, 30, 218, 10.1161/ATVBAHA.109.199299 Willingham, 2005, A strategy for probing the function of noncoding RNAs finds a repressor of NFAT, Science, 309, 1570, 10.1126/science.1115901 Sharma, 2011, Dephosphorylation of the nuclear factor of activated T cells (NFAT) transcription factor is regulated by an RNA-protein scaffold complex, Proc Natl Acad Sci U S A, 108, 11381, 10.1073/pnas.1019711108 Zimprich, 2004, Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology, Neuron, 44, 601, 10.1016/j.neuron.2004.11.005 Barrett, 2008, Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease, Nat Genet, 40, 955, 10.1038/ng.175 Abdelmegeed, 2011, PPARalpha expression protects male mice from high fat-induced nonalcoholic fatty liver, J Nutr, 141, 603 Pawlak, 2015, Molecular mechanism of PPARalpha action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease, J Hepatol, 62, 720, 10.1016/j.jhep.2014.10.039 Refolo, 2020, Inflammatory mechanisms of HCC development, Cancers, 12, 641, 10.3390/cancers12030641 Ruan, 2020, Therapeutic modulators of hepatic stellate cells for hepatocellular carcinoma, Int J Cancer, 147, 1519, 10.1002/ijc.32899